Black Diamond Therapeutics (NASDAQ:BDTX) Receives Outperform Rating from Wedbush
Wedbush restated their outperform rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a research note published on Friday morning,RTT News reports. The firm currently has a $11.00 price objective on the stock, down from their prior price objective of $16.00. Wedbush also issued estimates for Black Diamond Therapeutics’ Q1 2026 earnings […]
Wedbush restated their outperform rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a research note published on Friday morning,RTT News reports. The firm currently has a $11.00 price objective on the stock, down from their prior price objective of $16.00. Wedbush also issued estimates for Black Diamond Therapeutics’ Q1 2026 earnings […]
